Michael P. Graziano

Michael P. Graziano has extensive work experience in the pharmaceutical and biotechnology industry. Michael P. is currently serving as the Vice President and Head of Discovery and Translational Biology at Valo since April 2022. Before joining Valo, they served as the Chief Scientific Officer at TARA Biosystems, Inc. from August 2017 to March 2022.

Prior to their role at TARA Biosystems, Inc., Michael held the position of Vice President of Research Biology at MyoKardia from November 2015 to June 2017. Michael P. also worked as a Network Partner at Synergy Partners R&D Solutions from March 2014 to October 2015.

Michael has a distinguished tenure at Merck, where they held various executive roles. Michael P. served as the Executive Director in Cardiovascular Drug Discovery from March 2011 to April 2013, and as the Executive Director in External Basic Research in Cardiovascular and Diabetes from June 2008 to March 2011.

Before joining Merck, they worked at Schering Plough for many years. Michael P. held the position of Executive Director in Cardiovascular and Metabolic Diseases from November 1995 to March 2008. Prior to this, they were a Senior Scientist at Schering Plough from February 1989 to October 1995, where they had line management responsibility for three scientists and conducted research on G protein coupled receptor drug targets for obesity and diabetes.

Overall, Michael P. Graziano has a wealth of experience in research biology, drug discovery, and leadership roles in the pharmaceutical and biotechnology industry.

Michael P. Graziano received their PhD in Pharmacology from an undisclosed institution between the years of 1980 and 1985. Following that, they pursued a Fellowship in Pharmacology and Molecular Biology of G Proteins and GPCRs at UT Southwestern Medical Center, which lasted from 1985 to 1989.